BRD2 (65-459), His, Human Proteins
- Known as:
- BRD2 (65-459), histidine, Human Proteins
- Catalog number:
- Z03185-100
- Product Quantity:
- 100ug
- Category:
- Proteins
- Supplier:
- Genscript
- Gene target:
- BRD2 (65-459) His Human Proteins
Related genes to: BRD2 (65-459), His, Human Proteins
- Gene:
- BRD2 NIH gene
- Name:
- bromodomain containing 2
- Previous symbol:
- BRD2-IT1
- Synonyms:
- KIAA9001, RING3, D6S113E, NAT, FSRG1
- Chromosome:
- 6p21.32
- Locus Type:
- gene with protein product
- Date approved:
- 2000-07-25
- Date modifiied:
- 2017-01-12
Related products to: BRD2 (65-459), His, Human Proteins
Related articles to: BRD2 (65-459), His, Human Proteins
- Atopic dermatitis (AD) is a common and chronic inflammatory skin disease with global prevalence. Its clinical heterogeneity and complex molecular mechanisms pose significant challenges for the development of effective therapies. To explore AD molecular heterogeneity using lesional skin transcriptomic data, characterize their biological and immune profiles, and identify key genes underlying the differentiation. Differentially expressed genes were identified using DESeq2, followed by pathway and co-expression analyses via GSEA and WGCNA, respectively. Mitochondrial-related genes were extracted by intersecting DEGs and WGCNA modules with the MitoCarta3.0 database, and their functional relevance was assessed through GO and KEGG enrichment. Hub genes were identified by protein-protein interaction network analysis, which were subsequently used to construct a classification model. Transcriptional regulators were predicted using hTFtarget, while immune cell infiltration was quantified using CIBERSORT. Two molecular subgroups were identified. Cluster 1 was enriched in cell signaling and adhesion pathways, whereas Cluster 2 exhibited upregulation of oxidative phosphorylation and proteasome-related processes. A total of 85 mitochondrial-associated genes, primarily involved in energy metabolism, were differentially expressed between clusters. PPI network analysis identified four hub genes (BAD, BOLA1, CHCHD5, and ISOC2), which were significantly upregulated in Cluster 1. A hub gene-based classifier demonstrated strong discriminatory power (area under the curve > 0.7). Predicted key transcriptional regulators included ATF3, BRD2, BRD4, and CEBPA. Immune profiling revealed higher regulatory T cell infiltration in Cluster 1 and increased follicular helper T cells in Cluster 2. This study reveals two molecularly and immunologically distinct AD subtypes, characterized by differential mitochondrial function and immune microenvironment signatures. - Source: PubMed
Publication date: 2026/05/26
Yu YingyaoShang YuanyuanGe XinhongDong LingdiLi Kexin - Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic agent of several human cancers, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL), both of which still lack effective treatment options. Members of the bromodomain and extra-terminal domain (BET) family, especially bromodomain-containing protein 4 (BRD4), play important roles in RNA polymerase II-mediated transcriptional regulation and are required for the expression of many tumor-driving oncogenes in various cancer cells. Therefore, BET proteins have become attractive targets for anticancer drug development. Previous studies have demonstrated the high sensitivity of PEL cells to BET inhibitors, and BRD4 silencing effectively blocks tumor cell proliferation. In contrast, KSHV-infected immortalized endothelial cells display strong resistance to BET inhibitors, including (+)-JQ1. To further develop BRD-targeted therapies for KSHV-infected immortalized endothelial cells, we identified MZ-1 and SIM-1, two BRD4 PROTAC degraders, as effective inhibitors of cell growth in these cells. Mechanistically, these inhibitory effects depend on suppression of LANA translation through increased eIF2α phosphorylation in KSHV-infected cells. Similar LANA suppression was also observed following RNAi-mediated silencing of BRD2 or BRD4. Proteomic analysis identified unique protein candidates altered in MZ-1- and SIM-1-treated KSHV-infected immortalized endothelial cells compared with (+)-JQ1-treated cells. In summary, our study develops an effective strategy against KSHV-infected immortalized endothelial cells using selective BRD PROTACs, which may help improve therapeutic outcomes for KSHV-related malignancies in the future. - Source: PubMed
Publication date: 2026/06/01
Chen JungangFan JiaojiaoQin MargaretLin ZhenMu ShengyuDai LuQin Zhiqiang - Accumulation of adipocytes within the bone marrow is a frequently observed during aging. However, the molecular mechanisms underlying aberrant adipocyte differentiation in aged bone marrow remain largely unclear. In this study, we identified Ly-1 antibody reactive clone (Lyar) as an interacting partner of TGF-β activated kinase 1 (Tak1), a key molecule of non-canonical TGF-β signaling, through a proteomics approach, and demonstrated its involvement in the regulation of aging-related enhancement of adipogenesis. Lyar was not only implicated in the regulation of BMMSC proliferation but also may partly mediate the inhibitory effects of Bromodomain-containing protein 2 (Brd2). An age-associated decline in Lyar expression was associated with a reduction in FGF2-PI3K-Akt1 signaling activity in aged bone marrow. These findings suggest that Lyar may act as a context-dependent modulator of TGF-β signaling and may be involved in regulating proliferation and differentiation in BMMSCs. The age-related loss of Lyar may contribute to the complex mechanisms underlying enhanced adipogenesis in aged bone marrow, providing new insights into the regulation of mesenchymal stem cell fate during aging. - Source: PubMed
Publication date: 2026/05/27
Shinyashiki YuOnodera YutaKawashima YusukeIwawaki NatsumiTakehara ToshiyukiGoto KojiTeramura Takeshi - Bromodomain and extraterminal motif (BET) inhibitors, such as JQ1, are promising cancer therapeutics that target epigenetic regulators, particularly BRD4. However, resistance to BET inhibitors (BETi) limits their clinical utility, necessitating a better understanding of adaptive mechanisms. We identified BRD2 upregulation as a conserved response to BET inhibition across multiple cancer types and hypothesized that BRD2 compensates for BRD4 loss, sustaining essential transcriptional programs upon treatment. Consistent with this, BRD2 knockdown sensitized cancer cells to BETi in vitro, and combining BRD2 depletion and JQ1 treatment significantly impaired tumor growth in vivo. At the chromatin level, BRD2 and BRD4 ChIP-seq analysis of pancreatic cancer cells showed consistent BRD4 loss from chromatin after JQ1 treatment, while BRD2 displacement differed by sensitivity. Resistant cells maintained higher BRD2 occupancy than sensitive cells, suggesting a link between BRD2 retention and drug response. Mechanistically, NFYA mediates BRD2 upregulation as NFYA depletion attenuated BRD2 upregulation upon BETi treatment. Collectively, our findings establish BRD2 as a critical mediator of pan-cancer adaptive resistance to BETi and identify NFYA as a novel transcriptional regulator of this process. Co-targeting BRD2 or its regulatory network offers a rational strategy to enhance the durability and efficacy of BET-based therapies. - Source: PubMed
Publication date: 2026/05/02
Archasappawat SuyakarnJacques JulietteLee EunJungHwang Chang-Il - The engineered formation of ternary complexes, in which two proteins are bridged by small molecules such as PROTACs or molecular glues, is a prerequisite for the targeted enzymatic degradation of pathogenic proteins; however, the combined analysis of these ternary interactions during the drug discovery process remains challenging. Here, we introduce a proximity binding assay for the simultaneous measurement of binary and ternary interaction kinetics on a biosensor surface. Target proteins and the substrate binding subunit of ubiquitin E3 ligase are tethered to mobile swivel arms of a Y-shaped DNA scaffold. The Y-structure induces spatial proximity between the proteins and presents them to PROTAC analytes flown across the sensor. PROTAC-induced ternary complex formation is measured by fluorescence energy transfer (FRET), while binary interactions are detected by fluorescence quenching. The assay is applied to cereblon (CRBN) and von Hippel-Lindau (VHL) as E3 ligase substrate receptors, a range of compounds including AT1, MZ1, dBETs, and ARV-825 as PROTACs, and the two bromodomains of BRD2, BRD3, BRD4, and BRDT proteins as targets. Automated workflows enable the measurement of 384 real-time sensorgrams in a single run using picomole sample quantities. The insights into proximity-mediated binding kinetics can enable the development of PROTACs and molecular glues with improved properties for targeted protein degradation. - Source: PubMed
Publication date: 2026/04/21
Ponzo IreneSoldà AliceCrowe CharlotteDahl GöranJahodová TerezaHeerwig AndreasGeschwindner StefanCiulli AlessioRant Ulrich